Zhejiang Cdmo Pharmaceutical Co., Ltd

To investigate the safety, tolerability and pharmacokinetic characteristics of a single injection of HQ2216 injection in healthy adult subjects in China, and to compare its bioavailability and pharmacokinetic/pharmacodynamic characteristics with those of control drugs, so as to provide a theoretical basis for dose selection in subsequent studies.

Main purpose: To observe the time course of blood drug concentration of BIOS2220 (specification: 5 mg) after a single oral dose in healthy subjects in fasting and postprandial states, and to estimate the corresponding pharmacokinetic parameters; and to conduct human bioequivalence studies using amlodipine besylate tablets (trade name: Norvasc®/Norvasc®, specification: 5 mg) certified by Pfizer Pharmaceuticals Co., Ltd. as a control drug, to provide a reference for the registration and clinical application of the drug.

Primary study objective: To compare the effectiveness of loxoprofen sodium patch of Zhuhai Huitongda Pharmaceutical Co., Ltd. and the original research in the treatment of knee osteoarthritis. Secondary objective: To evaluate the safety of loxoprofen sodium patch in patients with knee osteoarthritis.